Cargando…
The association of hepatic steatosis and fibrosis with heart failure and mortality
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479901/ https://www.ncbi.nlm.nih.gov/pubmed/34583706 http://dx.doi.org/10.1186/s12933-021-01374-8 |
_version_ | 1784576358325682176 |
---|---|
author | Park, Jiyun Kim, Gyuri Kim, Hasung Lee, Jungkuk Lee, You-Bin Jin, Sang-Man Hur, Kyu Yeon Kim, Jae Hyeon |
author_facet | Park, Jiyun Kim, Gyuri Kim, Hasung Lee, Jungkuk Lee, You-Bin Jin, Sang-Man Hur, Kyu Yeon Kim, Jae Hyeon |
author_sort | Park, Jiyun |
collection | PubMed |
description | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. METHODS: We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 years who underwent a national health check-up from January 2009 to December 2012. The presence of hepatic steatosis and advanced hepatic fibrosis was determined using cutoff values for fatty liver index (FLI) and BARD score. We evaluated the association of FLI or BARD score with the development of iHF, hHF, mortality and CV death using multivariable-adjusted Cox regression models. RESULTS: A total of 28,524 (3.7%) individuals in the general population and 1422 (19.1%) pre-existing HF patients developed iHF and hHF respectively. In the multivariable-adjusted model, participants with an FLI ≥ 60 were at increased risk for iHF (hazard ratio [HR], 95% confidence interval [CI], 1.30, 1.24–1.36), hHF (HR 1.54, 95% CI 1.44–1.66), all-cause mortality (HR 1.62, 95% CI 1.54–1.70), and CV mortality (HR 1.41 95% CI 1.22–1.63) in the general population and hHF (HR 1.26, 95% CI 1.21–1.54) and all-cause mortality (HR 1.54 95% CI 1.24–1.92) in the HF patient group compared with an FLI < 20. Among participants with NAFLD, advanced liver fibrosis was associated with increased risk for iHF, hHF, and all-cause mortality in the general population and all-cause mortality and CV mortality in the HF patient group (all p < 0.05). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI and BARD score was significantly associated with the risk of HF and mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01374-8. |
format | Online Article Text |
id | pubmed-8479901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84799012021-09-29 The association of hepatic steatosis and fibrosis with heart failure and mortality Park, Jiyun Kim, Gyuri Kim, Hasung Lee, Jungkuk Lee, You-Bin Jin, Sang-Man Hur, Kyu Yeon Kim, Jae Hyeon Cardiovasc Diabetol Original Investigation BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. METHODS: We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 years who underwent a national health check-up from January 2009 to December 2012. The presence of hepatic steatosis and advanced hepatic fibrosis was determined using cutoff values for fatty liver index (FLI) and BARD score. We evaluated the association of FLI or BARD score with the development of iHF, hHF, mortality and CV death using multivariable-adjusted Cox regression models. RESULTS: A total of 28,524 (3.7%) individuals in the general population and 1422 (19.1%) pre-existing HF patients developed iHF and hHF respectively. In the multivariable-adjusted model, participants with an FLI ≥ 60 were at increased risk for iHF (hazard ratio [HR], 95% confidence interval [CI], 1.30, 1.24–1.36), hHF (HR 1.54, 95% CI 1.44–1.66), all-cause mortality (HR 1.62, 95% CI 1.54–1.70), and CV mortality (HR 1.41 95% CI 1.22–1.63) in the general population and hHF (HR 1.26, 95% CI 1.21–1.54) and all-cause mortality (HR 1.54 95% CI 1.24–1.92) in the HF patient group compared with an FLI < 20. Among participants with NAFLD, advanced liver fibrosis was associated with increased risk for iHF, hHF, and all-cause mortality in the general population and all-cause mortality and CV mortality in the HF patient group (all p < 0.05). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI and BARD score was significantly associated with the risk of HF and mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01374-8. BioMed Central 2021-09-28 /pmc/articles/PMC8479901/ /pubmed/34583706 http://dx.doi.org/10.1186/s12933-021-01374-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Park, Jiyun Kim, Gyuri Kim, Hasung Lee, Jungkuk Lee, You-Bin Jin, Sang-Man Hur, Kyu Yeon Kim, Jae Hyeon The association of hepatic steatosis and fibrosis with heart failure and mortality |
title | The association of hepatic steatosis and fibrosis with heart failure and mortality |
title_full | The association of hepatic steatosis and fibrosis with heart failure and mortality |
title_fullStr | The association of hepatic steatosis and fibrosis with heart failure and mortality |
title_full_unstemmed | The association of hepatic steatosis and fibrosis with heart failure and mortality |
title_short | The association of hepatic steatosis and fibrosis with heart failure and mortality |
title_sort | association of hepatic steatosis and fibrosis with heart failure and mortality |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479901/ https://www.ncbi.nlm.nih.gov/pubmed/34583706 http://dx.doi.org/10.1186/s12933-021-01374-8 |
work_keys_str_mv | AT parkjiyun theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT kimgyuri theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT kimhasung theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT leejungkuk theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT leeyoubin theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT jinsangman theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT hurkyuyeon theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT kimjaehyeon theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT parkjiyun associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT kimgyuri associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT kimhasung associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT leejungkuk associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT leeyoubin associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT jinsangman associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT hurkyuyeon associationofhepaticsteatosisandfibrosiswithheartfailureandmortality AT kimjaehyeon associationofhepaticsteatosisandfibrosiswithheartfailureandmortality |